To include your compound in the COVID-19 Resource Center, submit it here.

Femara letrozole: Phase III data; sNDA under review; marketed as second-line therapy

In a Phase III trial of 900 postmenopausal women with locally advanced, metastatic or recurrent

Read the full 151 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE